AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05460923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
Study NCT05460923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball Exercises
Description: trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
Study NCT06026657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06026657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06026657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06026657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06026657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Given IV
Study NCT06026657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV
Study NCT06298461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KleanLyte
Description: Laxative for colonoscopy bowel preparation
Study NCT06298461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bi-PegLyte
Description: Laxative for colonoscopy bowel preparation
Study NCT06301555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement learning algorithm powered cognitive and behavioral intervention
Description: Reinforcement learning algorithm powered cognitive and behavioral intervention
Study NCT06301555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and behavioral intervention
Description: cognitive and behavioral intervention
Study NCT06244303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)
Description: Toothpaste, toothbrush \& mouthwash regime
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
Study NCT06244303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)
Description: Toothpaste, toothbrush \& mouthwash regime
Study NCT06244303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manual toothbrush + Colgate dental cream
Description: toothpaste + toothbrush
Study NCT06244303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: manual toothbrush + Colgate dental cream
Description: toothpaste + toothbrush
Study NCT05265026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: A training session consists of 40 minutes as follows: 4x4 minutes at > 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: >85% of HRmax).
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: Sublingual dexmedetomidine (120 μg)
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Intravenous placebo of 0.9% saline administered over 40 minutes
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous placebo of 0.9% saline administered over 40 minutes
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Placebo
Description: Inert sublingual film
Study NCT06192615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual Placebo
Description: Inert sublingual film
Study NCT06557512 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiosurgery (SRS)
Description: Undergo Hypofractionated Stereotactic Radiosurgery
Study NCT06557512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI
Study NCT06557512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging
Study NCT06566326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and ketamine
Description: Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
Study NCT06566326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool
Description: Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
Study NCT05305495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
Study NCT04059757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: 1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
Study NCT05817539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid balance negativation
Description: During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion.
Study NCT05817539 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Body weight Stabilization
Description: During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation >3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.~In case of hemodynamic intolerance (NADN > 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min.
Study NCT05449587 — intervention group
Intervention type: OTHER
Intervention: MRI and PRO
Description: MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
Study NCT05300724 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered in this study.
Study NCT06399861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incubator ambient relative humidity (RH) of 70%
Description: The incubator will be set to an ambient relative humidity (RH) of 70%.
Study NCT06399861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incubator ambient relative humidity (RH) of 90%
Description: The incubator will be set to an ambient relative humidity (RH) of 90%.
Study NCT05096156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1® Daily Disposable Contact Lens
Description: Soft, spherical contact lens used to correct distance vision.
Study NCT04876040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SSO2 Downstream System
Description: 60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
Study NCT04876040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI + Impella
Description: Standard of Care Intervention
Study NCT04876040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI + Impella
Description: Standard of Care Intervention
Study NCT05861128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
Study NCT05950737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Description: All patients have undergone completion neck dissection following SNB in the process of standardization.
Study NCT06472960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Description: Moderate-intensity cycling on Ergoline Ergoselect 100
Study NCT06472960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity cycling
Description: Vigorous-intensity cycling on Ergoline Ergoselect 100
Study NCT06472960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Uninterrupted sitting in a quiet room
Study NCT05191121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP Alone
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
Study NCT05191121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP+Con-FES
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
Study NCT05191121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTP+WPHF-FES
Description: Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
Study NCT04337034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone supported and family-centred rehabilitation
Description: Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
Study NCT04337034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Information and blood pressure measurement
Description: Control group participants will be given information about stroke and their blood pressure will be measured.
Study NCT04337034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Information and blood pressure measurement
Description: Control group participants will be given information about stroke and their blood pressure will be measured.
Study NCT06258447 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Description: the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
Study NCT06258447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Description: the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
Study NCT06589453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants
Description: This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
Study NCT06589453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants
Description: Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
Study NCT05579197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower-limb robotic intervention
Description: The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~* The Optogait system; for a markerless gait analysis;~* The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients.
Study NCT06398496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise intervention will involve multiple exercise sessions completed (unsupervised) by participants. Exercise programs will be given to participants, matched to their current level of fitness as determined via a maximal cardiorespiratory fitness test, and will be adjusted via progressive overload every 1-2 weeks by an exercise and sports science professional.
Study NCT04990973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD)
Description: Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet).
Study NCT04990973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet).
Study NCT04652570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB119
Description: Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
Study NCT05149742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and audiometry evaluation
Description: For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires
Study NCT05149742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and audiometry evaluation
Description: For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires
Study NCT06544187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRS scan
Description: Magnetic Resonance Spectroscopy scan on the thigh
Study NCT06242392 — intervention group
Intervention type: GENETIC
Intervention: homologous recombination deficiency
Description: Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
Study NCT05320718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
Study NCT05320718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
Study NCT06544187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: Cardiopulmonary Exercise Test
Study NCT04916925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
Study NCT04916925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid
Description: CLOMID is adrug used for ovulation induction
Study NCT04674098 — intervention group
Intervention type: DEVICE
Intervention: The Beat Analytics System (BAS)
Description: There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
Study NCT06543654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnichroma
Description: Each participants had two kinds of veneers
Study NCT06543654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceram. X Spectra
Description: Ceram. X Spectra
Study NCT03867851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBsolvMIR
Description: Study drug IBsolvMIR
Study NCT03867851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Clinical praxis
Study NCT04866589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distribution of free face masks
Description: Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store.
Study NCT05200858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS - high-dose
Description: Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
Study NCT04849130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static reconstruction technique according to Schöttle
Description: In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
Study NCT04849130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic reconstruction technique according to Becher
Description: Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.